Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06265727 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Eligibility criteria expanded, about 10 words Study description expanded, about 9 words · Site details revised at 6 of 41 sitesv9 Show 2 more changesShow less
    • Study description expanded, about 9 words
    • Site details revised at 6 of 41 sites

    See this version in full on ClinicalTrials.gov ↗

  2. Study sites: 44 to 41v8
  3. Primary endpoints: 3 to 2 Enrollment target: 420 to 348 · Interventions: CRB-701 (Drug) to Anti-PD-1 (Drug), CRB-701 (Drug) · Secondary endpoints: 11 to 12 · 3 morev7 Show 6 more changesShow less
    • Enrollment target: 420 to 348
    • Interventions: CRB-701 (Drug) to Anti-PD-1 (Drug), CRB-701 (Drug)
    • Secondary endpoints: 11 to 12
    • Study description expanded, about 11 words
    • Site details revised at 15 of 44 sites
    • Study arms: 11 to 15

    See this version in full on ClinicalTrials.gov ↗

  4. Study sites: 30 to 44v6
  5. Site details revised at 2 of 30 sitesv5
Show 3 earlier versionsHide 3 earlier versions
  1. Study sites: 29 to 30v4
  2. Study sites: 7 to 29 Start date changed from estimate of Mar 30, 2024 to Apr 1, 2024v3 Show 1 more changeShow less
    • Start date changed from estimate of Mar 30, 2024 to Apr 1, 2024
  3. Trial status: Not Yet Recruiting to Recruiting Start date: Feb 20, 2024 to Mar 30, 2024 · Primary endpoints revised (3) · Secondary endpoints revised (11) · 2 morev2 Show 5 more changesShow less
    • Start date: Feb 20, 2024 to Mar 30, 2024
    • Primary endpoints revised (3)
    • Secondary endpoints revised (11)
    • Site details revised at 7 of 7 sites
    • Study title shortened, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to define a safe and effective dose of CRB-701 for participants with solid tumors that are expressing a protein called nectin-4. The main questions it aims to answer are: What is the the safe and effective dose of CRB-701? What cancers can be treated effectively with CRB-701? Participants will be asked to attend clinic and be given a intravenous infusion of CRB-701. They will have blood tests, CT or MRI Scans, and other assessments to measure whether CRB-701 has an effect on tumors.
Trial Details
NCT Number NCT06265727
Lead Sponsor Corbus Pharmaceuticals Inc.
Collaborators: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Conditions Solid Tumor, Adult
Enrollment 348 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov